EGFR and interstitial lung disease: Additionally, in all subjects with advanced or metastatic NSCLC treated with either EGFR-TKI or ICI, the OR of ILD incidence at any grade with VEGF/VEGFR inhibitors was 0.67 (95% CI, 0.49–0.94; p = 0.02), which showed a significantly lower incidence than that without VEGF/VEGFR inhibitors.